Cabio Biotech Wuhan Co Ltd

Jiabei You announced that due to overseas market sentiment and new EU regulatory requirements, the company's production and operations have been severely impacted and are not expected to return to normal within three months. Its stock will be placed under other risk alert. The company estimates first-half revenue of 55 million yuan, down 82.07 percent year-on-year, and a net loss attributable to shareholders of 101 million yuan, swinging from profit to loss. The impact is linked to the Nestlé infant formula recall earlier this year and new EU regulatory measures on arachidonic acid oil originating from China. The new EU rules require a certificate of absence of Bacillus cereus toxins for each shipment and impose a 50 percent inspection frequency, described by outsiders as the strictest controls in history. ARA is Jiabei You's core product, generating sales revenue of 388 million yuan last year, accounting for nearly 70 percent of total revenue. The company said it will respond by optimizing full-chain risk monitoring, strengthening customer communication, and accelerating new business development. It also warned that if full-year revenue in 2026 falls below 100 million yuan, the stock may be subject to delisting risk alert.

Cabio Biotech has released its 2026 half-year performance forecast, expecting a net loss attributable to owners of the parent company of about 101 million yuan in the first half, compared with a profit of 108 million yuan in the same period last year. The company said that due to the impact of overseas market sentiment and new regulatory requirements, production plans have been adjusted, and measures have been taken to promote business recovery. As product production and sales have not yet fully recovered, overall performance still shows a significant gap compared with the same period last year.

On the evening of July 24, Jiabeiyou issued a performance forecast stating that first-half 2026 revenue reached 55 million yuan, down 82.07 percent year-on-year. It expects a net loss attributable to shareholders of approximately 100.63 million yuan, a decline of 193.21 percent, and a non-recurring net loss of approximately 99.97 million yuan, down 200.25 percent. The company explained that due to overseas market sentiment and new regulatory requirements, production and sales have not yet fully recovered after adjusting production plans, leading to a sharp swing into the red. Jiabeiyou also disclosed that because its production and operations have been severely impacted and are not expected to return to normal within three months, its shares will be subject to other risk warnings, with the stock abbreviation changed to ST Jiabeiyou, while the daily price limit remains at 20 percent. As of the close on July 24, Jiabeiyou fell 3.02 percent to 9.94 yuan, with a total market capitalization of about 1.67 billion yuan, and its share price has dropped roughly 57 percent this year.

On the evening of July 24, multiple listed companies on the Shanghai and Shenzhen stock exchanges released important announcements. CATL reported first-half net profit of 43.284 billion yuan, up 41.98 percent year-on-year, and plans to distribute 14.11 yuan per 10 shares, as well as repurchase shares worth 20 billion to 40 billion yuan for cancellation. Hikvision posted first-half net profit of 7.896 billion yuan, a 39.57 percent increase, and intends to pay 5.5 yuan per 10 shares. TCL Technology's acquisition of a 45 percent stake in Guangzhou Huaxing Semiconductor has been approved by the Shenzhen Stock Exchange, after which it will hold 100 percent equity. Sunwoda's subsidiary Sunwoda Power plans to bring in Sungrow and Tianqi Lithium for a combined capital increase of 805 million yuan, corresponding to a 2.93 percent stake. Lens Technology's wholly-owned subsidiary signed a memorandum of cooperation with Intel, focusing on TGV advanced packaging technology. EVE Energy responded to LG Energy Solution's patent infringement lawsuit, stating that it has not infringed any patents. In addition, companies such as Xintian Technology, Pu Lian Software, and Beiken Energy suspended trading due to controlling shareholders planning changes in control rights. Cabio Biotech will be subject to other risk warnings, with its stock abbreviation changed to ST Cabio Biotech.